Generic Name: voretigene neparvovec
Brand Name: Luxturna
Manufacturer: Novartis Pharmaceuticals Canada Inc.
Indications: Vision loss, inherited retinal dystrophy
Manufacturer Requested Reimbursement Criteria1: As per Health Canada anticipated label
Submission Type: New
Project Status: Pending
Call For Patient Input: March 25, 2020
Patient Input Closed: May 14, 2020
Anticipated Date: April 23, 2020
Fee Schedule: Pending
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.